Avaliação da reatividade de anticorpos IgG para as proteínas S e N anti - SARS-CoV-2 em pacientes atendidos no HU-UFJF/EBSERH em Juiz de Fora
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora (UFJF)
Abstract
Covid-19 is a disease that has caused worldwide concern due to the high rates of
cases and deaths that have occurred. It is caused by the SARS-CoV-2 virus, a
betacoronavirus that has proteins in its viral structure capable of awakening the
immune response of individuals through infection or vaccination. In order to verify the
reactivity of IgG antibodies against SARS-CoV-2 proteins, a cross-sectional study on
patients treated at HU-UFJF/EBSERH units was carried out. Thus, sera from patients
collected in 2022 and 2023 were subjected to ELISA evaluation to verify the presence
of IgG antibodies against the spike and nucleocapsid proteins of SARS-CoV-2. Binding
avidity assays for these antibodies were conducted with samples from 2023. The
results of the serological analyzes showed that more than 90% of patients produced
IgG antibodies against virus proteins in both 2022 and 2023. Patients in the outpatient
unit with comorbidities present higher levels of reactivity against virus proteins
compared to those in the hospitalization unit. The percentage of drop in avidity
reactivity following treatment with the chaotropic agent urea was low, indicating that
the total IgG antibodies produced are of high avidity. 94.36% of the population
analyzed in 2023 were immunized with at least one dose of vaccination against Covid19. Both the 2022 and 2023 samples showed high IgG reactivity against the SARSCoV-2 proteins analyzed, with high avidity maintained. The association of these data
can be good indicators for verifying the development of protective immunity in the
population analyzed.
Description
Keywords
Citation
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwise noted, this item's license is described as Acesso Aberto

